Niagen Bioscience Inc (NASDAQ: NAGE) has a higher price-to-earnings ratio of 81.79x compared to its average ratio, The 36-month beta value for NAGE is at 2.10. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAGE is 49.81M, and currently, shorts hold a 5.62% of that float. The average trading volume for NAGE on June 12, 2025 was 840.99K shares.
NAGE) stock’s latest price update
Niagen Bioscience Inc (NASDAQ: NAGE)’s stock price has plunge by 0.39relation to previous closing price of 14.07. Nevertheless, the company has seen a 22.72% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-06-11 that LOS ANGELES–(BUSINESS WIRE)—- $NAGE #Biotech–Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world’s largest and most influential biotechnology event, c.
NAGE’s Market Performance
Niagen Bioscience Inc (NAGE) has seen a 22.72% rise in stock performance for the week, with a 45.17% gain in the past month and a 82.97% surge in the past quarter. The volatility ratio for the week is 4.75%, and the volatility levels for the past 30 days are at 4.15% for NAGE. The simple moving average for the past 20 days is 22.11% for NAGE’s stock, with a 121.65% simple moving average for the past 200 days.
Analysts’ Opinion of NAGE
Many brokerage firms have already submitted their reports for NAGE stocks, with Canaccord Genuity repeating the rating for NAGE by listing it as a “Buy.” The predicted price for NAGE in the upcoming period, according to Canaccord Genuity is $13 based on the research report published on May 27, 2025 of the current year 2025.
B. Riley Securities gave a rating of “Neutral” to NAGE, setting the target price at $2.40 in the report published on August 11th of the previous year.
NAGE Trading at 55.97% from the 50-Day Moving Average
After a stumble in the market that brought NAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.43% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAGE starting from Lopez Carlos Luis, who purchase 273 shares at the price of $7.86 back on Mar 07 ’25. After this action, Lopez Carlos Luis now owns 2,251 shares of Niagen Bioscience Inc, valued at $2,146 using the latest closing price.
Jaksch Frank L Jr, the Director of Niagen Bioscience Inc, sale 37,161 shares at $6.19 during a trade that took place back on Dec 13 ’24, which means that Jaksch Frank L Jr is holding 244,179 shares at $229,956 based on the most recent closing price.
Stock Fundamentals for NAGE
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.63 for the gross margin
The net margin for Niagen Bioscience Inc stands at 0.13. The total capital return value is set at 0.26. Equity return is now at value 33.47, with 20.83 for asset returns.
Based on Niagen Bioscience Inc (NAGE), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 4.57.
Currently, EBITDA for the company is 9.21 million with net debt to EBITDA at -2.85. When we switch over and look at the enterprise to sales, we see a ratio of 9.94. The receivables turnover for the company is 13.89for trailing twelve months and the total asset turnover is 1.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.66.
Conclusion
In conclusion, Niagen Bioscience Inc (NAGE) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
